No Data
No Data
No Data
No Data
No Data
CASI Pharmaceuticals Discloses Material Development Relating To Its Dispute With Juventas
On April 8, 2024, CASI Pharmaceuticals, announced that, with respect to the Company's previously announced dispute with Juventas Cell Therapy Ltd., an emergency arbitrator appointed by the Hong Kong I
BenzingaApr 8 17:03 ET
CASI Pharmaceuticals Gets Emergency Injunctive Relief in Dispute With Juventas Cell Therapy >CASI
CASI Pharmaceuticals Gets Emergency Injunctive Relief in Dispute With Juventas Cell Therapy >CASI
Dow JonesApr 8 17:02 ET
CASI Pharmaceuticals: Order Prohibits Juventas From Commercializing CNCT19 >CASI
CASI Pharmaceuticals: Order Prohibits Juventas From Commercializing CNCT19 >CASI
Dow JonesApr 8 17:02 ET
CASI Pharmaceuticals Wins Emergency Relief Regarding the Dispute With Juventas Cell Therapy Ltd Prohibiting Juventas From Commercializing CNCT19
On April 8, 2024, CASI Pharmaceuticals, Inc., a Cayman Islands incorporated company ("CASI" or the "Company") announced that, with respect to the Company's previously announced dispute with Juventas
BenzingaApr 8 07:34 ET
Recap: CASI Pharmaceuticals Q4 Earnings
CASI Pharmaceuticals (NASDAQ:CASI) reported its Q4 earnings results on Thursday, March 28, 2024 at 07:00 AM.Here's what investors need to know about the announcement.EarningsCASI Pharmaceuticals misse
BenzingaMar 28 08:20 ET
CASI Pharmaceuticals GAAP EPS of -$2.02, Revenue of $33.88M
Seeking AlphaMar 28 07:22 ET
No Data
No Data